Migdal Insurance & Financial Holdings Ltd. Has $1.11 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 478.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,078 shares of the medical research company’s stock after purchasing an additional 1,719 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in Thermo Fisher Scientific were worth $1,107,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Coppell Advisory Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $33,000. Live Oak Investment Partners purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at $36,000. Tyler Stone Wealth Management bought a new position in Thermo Fisher Scientific during the 2nd quarter valued at $37,000. Raleigh Capital Management Inc. grew its stake in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares in the last quarter. Finally, Cedar Mountain Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group upped their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Raymond James increased their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $604.69.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $547.25 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The stock has a market capitalization of $208.89 billion, a P/E ratio of 35.42, a PEG ratio of 2.33 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $571.57 and its 200 day moving average is $527.01.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same period last year, the company earned $5.40 earnings per share. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.